NCT04943848 - rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant

Interventions

BIOLOGICAL

rHSC-DIPGVax

Off-the-shelf, neoantigen heat shock protein vaccine

DRUG

Balstilimab

BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

DRUG

Zalifrelimab

ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)

Trial Locations (3)

60611

RECRUITING

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

92868

RECRUITING

Children's Health Orange County (CHOC), Orange

02215

RECRUITING

Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston

All Listed Sponsors

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Children's Hospital of Orange County

OTHER

collaborator

University of Calgary

OTHER

lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER